Every decade or two, there are medical discoveries made that thoroughly shake up the entire pharmaceutical industry. Drugs such as penicillin, insulin, and thorazin not only changed the scope of how severe medical conditions could be treated, but they were instrumental in helping thousands, if not millions of people, live more comfortable and healthy lives.
CBD is, without a doubt, this decade’s superstar. More and more people have started to take notice as testimonials and tons of anecdotal evidence about cannabidiol’s effectiveness pile up. CBD works against pain, inflammation, anxiety, and a host of other conditions quite well. So well, in fact, that people have begun thinking about how CBD can be applied more radically; there’s a new study that will study the effectiveness of CBD on dogs.
The University of Pennsylvania, School of Veterinary Medicine (UPSVM) partnering with Dixie Brand Inc., a Denver-based cannabis producer, launched the first-ever scientific study into the efficacy of CBD therapy to help relieve the symptoms of canine joint-related immobility. The study will be led by Kimberly Agnello, an Associate Professor of surgery at UPSVM.
Although there’s plenty of anecdotal evidence on the effectiveness of CBD, most medical professionals are wary of recommending it since there has been little scientific research on CBD.
“We want to validate whether this is actually helpful and it’s something we should be recommending,” says Agnello, “Up until now, there haven’t been too many great studies showing that CBD is beneficial in helping to relieve pain in people or dogs with arthritis.”
Her team will study canines afflicted with osteoarthritis. The goal is to establish which CBD treatments deliver the best results. The dogs will be divided into three groups; one will be given CBD only, another a Dixie Brands Inc. affiliate-developed CBD formula, and the third group will be get placebos.
This study could also help researchers understand the effects of CBD in humans. You see, unlike rats that live in a controlled environment, the lab, dogs are exposed to the same environment humans are. They are exposed to the same toxins in the air, food, and atmosphere. The lifestyle of a pet dog closely mirrors that of its owner, thus the information culled from these studies could be used for future studies on people.
This wasn’t Agnello’s first attempt, though. She and her team tried to study CBD years ago but were held back by regulations. Although CBD isn’t psychoactive, it is obtained from the same marijuana plant as THC, and it was listed as a Schedule 1 substance. However, it has become easier to research the compound now that regulations have become less strict on hemp.
Experts agree that CBD industry participants like Youngevity International Inc. (NASDAQ: YGYI) and ChineseInvestors.com Inc. (OTCQB: CIIX) will be eager to read the findings of this study since the research could broaden the tested applications of CBD.
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com